Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer

Keyphrases

• Docetaxel 100%
• Neoadjuvant Therapy 100%
• Filgrastim 100%
• Locally Advanced Breast Cancer 100%
• Dose-dense 100%
• Neoadjuvant 66%
• Granulocyte Colony-stimulating Factor (G-CSF) 66%
• 4-cycle 66%
• Hematotoxicity 66%
• Hepatic Function 33%
• Renal Function 33%
• Number of Patients 33%
• Pathological Complete Response 33%
• Chemotherapy 33%
• Radiotherapy 33%
• Progressive Disease 33%
• Progression-free 33%
• Cyclophosphamide 33%
• Metastatic Disease 33%
• Infiltrating Ductal Carcinoma 33%
• Radiologic 33%
• Severe Pain 33%
• Tumor Response 33%
• Doxorubicin 33%
• Poor Differentiation 33%
• Compliance Behavior 33%
• Complete Blood Count 33%
• ER + 33%
• Neutropenic Fever 33%
• Eligibility Requirements 33%
• Advance Breast Cancer 33%
• Treatment-related Fatigue 33%
• Lobular Cancer 33%
• Adjuvant Docetaxel 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Docetaxel 100%
• Filgrastim 100%
• Granulocyte Colony Stimulating Factor 66%
• Malignant Neoplasm 33%
• Neoplasm 33%
• Chemotherapy 33%
• Progression Free Survival 33%
• Cyclophosphamide 33%
• Doxorubicin 33%
• Tamoxifen 33%
• Breast Carcinoma 33%
• Febrile Neutropenia 33%
• Adjuvant 33%
• Diseases 33%